arrow
M

Michael Braun

royal college of surgeons of england
H指数:46
被引数:8,377

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Overall survival for bevacizumab therapy in metastatic colorectal cancer: an updated analysis of the TRAVASTIN study

贝伐珠单抗疗法在转移性结直肠癌中的总生存期:TRAVASTIN研究的更新分析

2025-11-120
PRE
A clinical rule-based indicator to identify recurrence of colorectal cancer after curative resection using linked routinely collected national data

一种基于临床规则的指标,用于识别在根治性切除术后使用关联的常规收集的国家数据来判定结直肠癌的复发

2025-11-010
OAAI
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials

HER2+早期乳腺癌降级新辅助治疗后生存预测:一项基于三项WSG试验的合并分析

2025-08-050
PREAI
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial

免疫调节基因网络预测在WSG-ADAPT-TN试验中,三阴性乳腺癌对降级、无蒽环类的新辅助化疗的治疗反应和生存情况。

2025-03-260
OA
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer A Secondary Analysis of a Randomized Clinical Trial

三阴性乳腺癌患者中的基因改变、治疗反应和生存情况:一项随机临床试验的二次分析

2025-02-260
OA
Oncological Outcomes From Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases

结直肠癌腹膜转移经细胞减灭术联合温热腹腔化疗的肿瘤学结果

2024-12-120
OAAI
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer
2024-11-010
OAAI
Ribosome Quality Control mitigates the cytotoxicity of ribosome collisions induced by 5-Fluorouracil
2024-10-010
OAAI
Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTcycle trial (n=4,334)
2024-05-020
PRE
Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter WSG-ADAPTcycle trial (n=5,290)
2024-05-020
PRE
HER2DX genomic assay in triple-negative breast cancer (TNBC) patients treated with 12-weeks of neoadjuvant chemotherapy: a correlative analysis from WSGADAPT-TN phase II trial
2024-05-020
PRE
Circulating tumor DNA (ctDNA) for prediction of pathologic complete response (pCR) after 12 weeks of pembrolizumab plus trastuzumab plus pertuzumab in HER2-enriched early breast cancer: WSG-Keyriched-1 trial
2024-05-020
PRE
Exploring Circulating Leukocyte RNA Expression: Implications for Treatment Outcomes and Immune-Related Adverse Events in Patients with Triple Negative Breast Cancer Enrolled in the GeparNuevo Trial
2024-05-020
PRE